ReviewNeuropharmacology2018
The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.
Review in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- The 5-HTPharmacology research & perspectives · 2021Trial
- The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.Pharmacology, biochemistry, and behavior · 2019Trial
- Review
- Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.Nature communications · 2024Article
- Review
- Neural circuits controlling choice behavior in opioid addiction.Neuropharmacology · 2023Review
- 3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.The Journal of pharmacology and experimental therapeutics · 2023Article
- The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal.Pharmacology, biochemistry, and behavior · 2023Article
- Pharmacological Mechanism of the Non-hallucinogenic 5-HTACS chemical neuroscience · 2023Article
- Confronting the challenge of failed translation in medications development for substance use disorders.Pharmacology, biochemistry, and behavior · 2021Article
- 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.Addiction biology · 2021Article
- Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.ACS chemical neuroscience · 2021Article
- Chronic Lorcaserin Treatment Reverses the Nicotine Withdrawal-Induced Disruptions to Behavior and Maturation in Developing Neurons in the Hippocampus of Rats.International journal of molecular sciences · 2021Article
- Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Review
- Serotonin transporter protein in autopsied brain of chronic users of cocaine.Psychopharmacology · 2020Article
- Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.Drug and alcohol dependence · 2020Article
- The Neuroscience of Drug Reward and Addiction.Physiological reviews · 2019Review
- Ligand-directed serotonin 5-HTEuropean journal of pharmacology · 2019Article
- Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.Experimental and clinical psychopharmacology · 2019Article
- Impaired cognitive behavioral flexibility following methamphetamine or high caloric diet consumption: a common 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Substance abuse is serious public health problem for which there are few effective pharmacotherapies. Traditional strategies for drug development have focused on antagonists to block the abuse-related effects of a drug at its site of action, and agonists to replace/mimic the effects of the abused substance. However, recent efforts have targeted receptors, such as serotonin (5-HT)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.